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Niemann-Pick type C is a neurodegenerative lysosomal storage disorder caused by mutations in either of two genes,
npc1 and npc2. Cells lacking Npc1, which is a transmembrane protein related to the Hedgehog receptor Patched, or
Npc2, which is a secreted cholesterol-binding protein, have aberrant organelle trafficking and accumulate large
quantities of cholesterol and other lipids. Though the Npc proteins are produced by all cells, cerebellar Purkinje
neurons are especially sensitive to loss of Npc function. Since Niemann-Pick type C disease involves circulating
molecules such as sterols and steroids and a robust inflammatory response within the brain parenchyma, it is crucial to
determine whether external factors affect the survival of Purkinje cells (PCs). We investigated the basis of
neurodegeneration in chimeric mice that have functional npc1 in only some cells. Death of mutant npc1 cells was not
prevented by neighboring wild-type cells, and wild-type PCs were not poisoned by surrounding mutant npc1 cells. PCs
undergoing cell-autonomous degeneration have features consistent with autophagic cell death. Chimeric mice
exhibited a remarkable delay and reduction of wasting and ataxia despite their substantial amount of mutant tissue
and dying cells, revealing a robust mechanism that partially compensates for massive PC death.
Citation: Ko DC, Milenkovic L, Beier SM, Manuel H, Buchanan J, et al. (2005) Cell-autonomous death of cerebellar Purkinje neurons with autophagy in Niemann-Pick type C
disease. PLoS Genet 1(1): e7.
Introduction
Niemann-Pick type C (NPC) is a devastating autosomal
recessive neurodegenerative disorder characterized by the
accumulation of cholesterol and other lipids in viscera and
the central nervous system. The clinical presentation typically
includes progressive ataxia, dystonia, and dementia, ﬁrst
presenting in early childhood and ultimately leading to death
in the early teens [1]. NPC is one of over 40 known lysosomal
storage disorders (reviewed in [2,3]), which collectively have
an incidence of one in 8,000 live births [4]. The speciﬁc
molecules that accumulate in each disease vary, but most of
the disorders share the feature of prominent neurological
symptoms. Though great progress has been made in
characterizing the biochemical and genetic defects in these
diseases, the pathways that lead from these defects to cell and
tissue dysfunction are inadequately understood.
The decline in neurological function in NPC patients is
caused by mutations in either the npc1 or npc2 gene [5–7].
Npc1 is a multiple-membrane-spanning late endosomal/
lysosomal protein that can bind cholesterol [8] and acts as a
transmembrane pump when expressed in bacteria [9]. The
Npc1 protein has a sequence related to the ‘‘sterol sensing
domain’’ of known regulators of cholesterol metabolism
(SCAP and HMG-CoA reductase) and Patched, a receptor for
the secreted developmental signaling protein Hedgehog. The
exact role of Npc1 in regulating lipid homeostasis and in
maintaining neurological function is far from clear. Even less
is known about Npc2, the small cholesterol-binding protein
[10–12] responsible for a minority (,5%) of NPC cases.
Phenotypes similar to human NPC are seen in two mouse
strains, C57BLKS/J spm [13] and BALB/c npc1
nih [14], both of
which harbor spontaneous mutations in npc1 [6]. The most
striking and well-documented histological change in npc1
mice is the progressive loss of cerebellar Purkinje cells (PCs)
[15,16]. Stereotactic cell counting conﬁrmed that the PC is
the type that exhibits the greatest percentage loss in npc1
mice (,10% remaining at 10 wk) but surprisingly revealed
that glia in the corpus callosum have a greater early reduction
in number (48% for glia versus 13% for PCs, at 3 wk) [17].
This early decline in glia and the detection of Npc1 protein in
astrocytic processes [18] led to the idea that the primary
function of the Npc1 protein may be in glia and that loss of
PCs and other neurons may be a secondary consequence of
glial dysfunction [17,19]. However, Npc1 mRNA is abundantly
present in neurons as well as glia throughout the brain [20].
Thus, it is unclear which cells in the brain require Npc1
protein and why PCs degenerate in mice lacking Npc1.
Four broad categories of possible explanations for the PC
degeneration have emerged (Figure 1). (1) Npc1 is required
within PCs and loss of the protein results in degeneration as a
consequence of the toxic accumulation of lipids. High
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death by altering membrane rigidity, forming intracellular
crystals that may interfere with organelle function, or
triggering apoptotic signaling events [21]. (2) Npc1 is
required within PCs and loss of the protein causes a
deﬁciency at speciﬁc subcellular locations. In this model,
the accumulation of cholesterol and other lipids is not
harmful per se, but the diminished capacity to transport these
or other molecules to the correct places within the cell leads
to degeneration. (3) Npc1 is required within glia or another
cell type within the cerebellum, or in a distant organ such as a
secretory gland, and loss of the protein results in degener-
ation of PCs through a deﬁciency in a secreted molecule. This
could be a trophic factor or possibly even cholesterol itself, as
studies have shown that glia-derived cholesterol is required
for synaptogenesis [22]. (4) Loss of Npc1 function results in
the release of toxic/pro-inﬂammatory compounds into the
local environment or systemic circulation, causing PC
degeneration.
In this study, we employed chimeric mice to help resolve
the fundamental mystery of why neurons degenerate in NPC
disease. This powerful approach can distinguish intrinsic and
extrinsic causes of cell death but has only rarely been used to
study human neurodegenerative disease [23,24]. The results
indicate that PC loss in npc1
 /  mutants is a cell-autonomous
process, i.e., Npc1 function is critical within PCs. Ultra-
structural and biochemical analyses support the idea that this
cell-autonomous loss is due to the activation of a particular
genetic program, autophagy, that leads to cell death.
Results
Pattern of Cerebellar Degeneration in npc1 Mice
As a ﬁrst step it was important to observe and measure
progressive PC loss. PC loss in the cerebellar vermis
progressed in an anterior (lobule I) to posterior (lobule X)
sweep, as previously reported [15,16] (Figure 2A and 2B).
There was a normal number and density of PCs in cerebellar
sections from 30-d-old npc1
 /  mice. At 50 d, most PCs in
lobules I–III were no longer present. By 70 d, only lobule X
PCs remained intact.
We next investigated whether Bergmann glia are affected
in npc1
 /  mice. Bergmann glia appose the PC soma and
extend processes into the molecular layer that sheaths the PC
dendritic trees (reviewed in [25]). Loss or dysfunction of these
glia could precede and precipitate the PC loss. In contrast to
the degeneration and loss of PCs, Bergmann glia stained with
anti-S100b maintain their density and their characteristic
radial morphology, even at 70 d, in all lobules (Figure 2C).
Oligodendrocytes, the glia that myelinate axons, were normal
in distribution and cell body morphology (Figure 2D).
Staining of myelin revealed axonal spheroids as previously
reported (Figure 2E) [15,26]. Granule cells, the most abundant
neurons in the cerebellum, were also grossly normal based on
anti-GABAa6 staining (data not shown). This indicates that
loss of PCs in npc1 mice is not due secondarily to a loss or
other obvious morphological derangement of these other cell
types. However, these observations do not rule out the
possibility that a more subtle dysfunction in these cells
contributes to the degeneration of PCs in npc1mice.
Figure 1. Models of PC Degeneration in npc1 Mice
Four basic mechanisms are depicted. (1) The accumulation of cholesterol,
sphingolipids, or other molecules within PCs lacking Npc1 could be toxic.
(2) Loss of Npc1 function could cause a block in trafficking that leads to a
localized subcellular deficiency in lipids and/or proteins. (3) Other cells,
most likely glia, could produce a secreted factor, such as apoE-
cholesterol or a trophic factor required for PC survival, whose export is
reduced or blocked without Npc1 function. (4) Any cell type in the npc1
mouse could produce toxic metabolites, such as released lysosomal
hydrolases or beta amyloid, that could kill surrounding cells or
particularly susceptible cell types regardless of genotype.
DOI: 10.1371/journal.pgen.0010007.g001
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Synopsis
Niemann-Pick disease type C is a deadly neurodegenerative disease
that is most often due to mutations in a gene called npc1.A sa
consequence of intracellular lipid trafficking defects, patients with
Niemann-Pick type C, and mice with the same disease, lose an
important class of cerebellar neurons called Purkinje cells (PCs).
Npc1 (the protein coded by npc1) might be needed in other cell
types to produce substances that nourish PCs or within the PCs
themselves. To see which is true, the researchers constructed
genetically mosaic mice in which some cells have mutant Npc1 and
some have normal Npc1 function. In the cerebella of these mosaic
mice, PCs lacking Npc1 continued to die even while surrounded by
normal cells, while normal PCs appeared unaffected by their partially
mutant surroundings. From these findings, the researchers con-
cluded that the neurodegeneration is due to a problem within PCs
and not due to a lack of supporting factors provided by other cells
or an extrinsic toxic or inflammatory insult. Npc1 probably functions
within PCs to allow critical transport processes necessary for cell
survival. The researchers also found that the degenerating PCs
undergo a complex process called autophagy in which the cells
sense a lack of key nutrients and start to break down their own
structures to feed themselves. By identifying exactly which cells
require Npc1 function, the researchers set the stage for investigating
the exact molecular roles of Npc1 protein in the cells where it is
most needed.The anterior-to-posterior gradient of PC loss provides the
opportunity to determine how cholesterol accumulation
changes in relation to the PCs. If intracellular cholesterol
accumulation is toxic to PCs, a correlation is expected
between the amount of cholesterol and the rate or severity of
degeneration. Instead, we ﬁnd that at 30 d, intracellular
cholesterol accumulation is noted even in lobule X PCs
(which do not degenerate during the normal npc1 mouse life
span). We did not ﬁnd any consistent difference in ﬁlipin
staining of cholesterol among the different cerebellar lobules
in npc1 mice (Figure 2F). Therefore, lysosomal cholesterol
accumulation per se is not sufﬁcient to explain the pattern of
PC death.
PC Degeneration in npc1 Mice Is Cell-Autonomous
To determine whether PC loss is due to dysfunction within
the PCs, alterations in the surrounding glia and micro-
environment, or a combination of both, we generated mice
containing a mixture of npc1 mutant and wild-type cells.
Morulas derived from mating npc1 heterozygotes (BALB/c
npc
nih/þ) and from matings of wild-type mice homozygous for
a ubiquitously expressed green ﬂuorescent protein (GFP)
gene (FVB.Cg-Tg(GFPU)5Nagy/J; [27]) were aggregated to
form chimeric embryos. A quarter of the embryos from npc1/þ
parents should be homozygous for the npc1 mutation, but
these embryos could not be distinguished at the time of
morula isolation, so the embryos derived from aggregation
had to be analyzed later to determine which were the useful
chimeras. Chimeras were also created in which npc1 mutant
cells were marked with GFP (genetic background 75% FVB/
25% BALB/c; see Materials and Methods for crosses), ensuring
that the results were independent of the genetic background.
Of 33 chimeric mice generated, seven were of the desired
genotype, as determined using PCR analysis (two npc1
 / 
BALB/c$GFP; two npc1
 /  75% FVB/25% BALB/c$CD-1;
three npcl
 /  75%FVB/25% BALB/c$C57BL6/J) (Figure 3A).
These seven mice had wild-type contributions ranging from
11% to 61% based on skin ﬂuorescence, granule cell counts,
and lobule X PC counts. Wild-type contributions estimated
from skin ﬂuorescence always corresponded well to the value
determined from cell counts; the numbers differed by 4%–
22% (see Table 1). The reliability of skin ﬂuorescence and
granule cell counts as estimates of overall chimerism
percentage was further validated by examination of two
npc1 heterozygous chimeras that demonstrated similar chi-
merism percentage whether determined by skin, granule cell
counts, or, most importantly, PC counts (Table 1). For each
chimeric mouse, all PCs in ﬁve sagittal sections of the
cerebellar vermis were counted and each cell’s genotype was
determined based on GFP ﬂuorescence. Characteristics of the
mice are summarized in Table 1.
The data from all seven mice demonstrated that PC
degeneration in npc1
 /  mice is primarily a cell-autonomous
process. PC counts revealed that the presence of a milieu that
was more than 60% wild-type was insufﬁcient to prevent npc1
PC loss. In the two oldest mice analyzed (190 d), chimeras 4.4
and 4.8 (C4.4 and C4.8), nearly all npc1 PCs had degenerated,
including those in lobule X. In these mice, the wild-type
contributions were estimated to be 54% and 61%. Mutant
npc1 PCs were observed at densities of 0.5 and 0.6 PCs/mm in
the mice, strikingly lower than the expected densities of 12
and 10 PCs/mm if no degeneration had occurred (Figure 3B).
Expected PC densities, assuming no degeneration, were
calculated by multiplying the observed density in 30 d
npc1
 /  mice by the percentage of chimerism. Similar
measurements were made in all seven chimeras. Two mice
sacriﬁced at a younger age (120 d; C2.1 and C5.8) had lost all
but a few npc1 PCs, which were primarily in lobule X. The
results demonstrate that surrounding wild-type cells are
unable to prevent npc1 PC degeneration. These four mice
also demonstrate that lobule X PCs will eventually degener-
ate; their loss is delayed rather than completely prevented.
Three chimeric mice were analyzed at 70 d, at the end of
the normal life span of npc1
 /  mice. One of these three mice
had a substantial wild-type contribution (33%; C1.4), but no
signiﬁcant prevention or delay of npc1 PC degeneration was
observed (Figure 3C). The vast majority of mutant PCs (except
those in lobule X) degenerated despite the presence of a
signiﬁcant fraction of wild-type cells (Figure 3D and 3E).
In contrast to the mutant PCs, wild-type PCs did not
degenerate in most of the chimeric mice. The observed wild-
type PC densities agreed well with the expected densities
based on the wild-type contribution in each mouse (Figures
3F and 3G). The lone exceptions occurred in the two mice
with 11% and 13% wild-type contribution. These mice were
expected to have a very low number of wild-type PCs, but
there were even fewer than expected. No signiﬁcant decrease
in wild-type PC density was observed in the other ﬁve
chimeric mice, including C2.1, which was expected to have
only a marginally greater wild-type contribution (15%).
Although ﬂuctuation in how small numbers of wild-type cells
are distributed and consequent variability among analyzed
sections provide a likely explanation, another interpretation
is that when very few wild-type cells are present, the entire
cerebellum begins to break down during the late stages of
cerebellar degeneration. Toxins released by dying cells could
contribute to PC loss but are clearly not the main cause of
neurodegeneration.
Other Histologic Features of npc1 Chimeric Mice
Examination of the relationships of other cell types to the
PCs in the chimeras provides further evidence for the cell-
autonomous nature of PC degeneration. Microglia have been
observed in the cerebellum of npc1
 /  mice, but their role in
PC degeneration is unclear [28]. Microglia are the phagocytic
cells of the central nervous system, and their presence is
indicative of an inﬂammatory process. The appearance of
microglia within the cerebellum follows the anterior–poste-
rior pattern of PC death. In wild-type mice or npc1 mutant
mice at 30 d, almost no microglia are observed (data not
shown). In 50-d-old npc1 mutant mice, very few microglia are
present in lobule X (Figure 4A). The other cerebellar lobules
have numerous microglia in the white matter tract and
granule cell layer prior to the loss of PCs (Figure 4B). After
more extensive PC loss (lobules I–IV at 50 d and I–IX at 70 d),
microglia also appear in the molecular and PC layers (Figure
4C). Thus, the arrival of microglia coincides with PC loss.
However, the inﬁltration of numerous microglia is not
sufﬁcient to trigger PC degeneration. Microglia were present
in all the chimeric mice (though to a lesser extent in mice
sacriﬁced at a later age) and were in close proximity to wild-
type PCs (Figure 4D, white arrows). Despite this close
association, there was no decrease in wild-type PC density
in the chimeras except the two noted above. Furthermore, if
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nism of PC loss, then wild-type and mutant PCs should
demonstrate comparable decline percentages. This is not the
case in any of the chimeras.
Mutant PC loss occurred even with wild-type Bergmann
glia in the immediate vicinity. In the chimeras, PCs were
strikingly absent in regions containing abundant wild-type
glia (Figure 4E, arrowheads). Conversely, wild-type PCs
(Figure 4F, white arrows) survived even when surrounded by
mutant glia (Figure 4F, arrowheads). Oligodendrocytes of
both genotypes were scattered in the cerebellar white matter
of the chimeric mice (Figure 4G). The loss of mutant PCs is
unlikely to be due to the lack of a secreted factor from
supporting cells. If Npc1 were necessary for the efﬁcient
secretion of this hypothetical survival factor, then surround-
ing wild-type glia should have been able to provide the
molecule to mutant PCs. The ongoing degeneration of npc1
mutant PCs surrounded by a high percentage of wild-type
cells indicates that cell-autonomous mechanisms play the
primary role in PC death.
Prevention of Ataxia and Weight Loss in Chimeric Mice
Despite substantial loss of npc1 PCs, some chimeric mice
displayed minimal ataxia and no weight loss. Ataxia was
assessed through measuring agility on a balance beam [29]
and by quantifying step size in a gait assay [30]. At 190 d, more
than twice the normal life span of npc1 mice, the two
chimeras with more than 50% wild-type cells (C4.4 and C4.8)
displayed no signs of wasting and only minimal ataxia (Figure
5). Even more impressive was a mouse with only 15% wild-
type cells (C2.1) that had signiﬁcantly reduced symptoms. The
genetic background of the mutant cells appears to inﬂuence
the rate of disease progression. Delayed symptoms were not
noted in C5.2 and C5.6, which had only slightly less wild-type
contribution than C2.1. The npc1 mutant cells in the C5.2 and
C5.6 mice were derived from a 75% FVB/25% BALB/c$GFP
þ/
þ background, and mutant mice of this genetic background
demonstrated a faster progression of disease compared to the
mutation in the BALB/c background of C2.1 (average life span
of 67 6 5 d versus 81 6 8 d). It is remarkable that some 40%
of the PCs can die without leading to severe ataxia or weight
loss, and that even much smaller numbers of wild-type cells
(15%) provide temporary protection against wasting, ataxia,
and death.
Activation of Autophagy in Degenerating PCs
The evidence from chimeric mice highlighted the impor-
tance of possible cell-autonomous mechanisms of PC degen-
Table 1. Genotype and Percentage Chimerism for the Mice Used in This Study
ID Strain/Genotype Age at
Sacrifice
(Days)
Percent Wild-Type Mean
Percent
Wild-Type
Onset of
Weight
Loss (Day)
Severe
Ataxia
(Day)
c Skin PCs
a Granule Cells
b
GFP FVB.Cg-Tg(GFPU)5Nagy/J 100 98 (63)
d 95 (63) Never No
npc1/npc1 BALB/c npc1
nih 00 0 5 2 ( 66) 56 (69)
C1.1 npc1
þ/ $GFP 70 80 85 (64) 86 (63) 84 Never No
C4.6 npc1
þ/ (GFP)$CD1 190 50 35 (65) 40 (613) 42 Never No
C1.4 npc1
 / $GFP 70 40 27 (65)
e 31 (66) 33 Never ND
f
C2.1 npc1
 / $GFP 120 20 NM
g 10 (65) 15 70 90
C4.4 npc1
 / (GFP)$CD1 190 65 NM
g 43 (611) 54 Never No
C4.8 npc1
 / (GFP)$CD1 190 65 NM
g 58 (66) 61 Never No
C5.2 npc1
 / (GFP)$C57 70 5 5 (61)
e 18 (66) 11 55 55
C5.6 npc1
 / (GFP)$C57 70 10 9 (62)
e 17 (67) 13 55 55
C5.8 npc1
 / (GFP)$C57 120 30 NM
g 34 (611) 32 55 76
aPercentage wild-type based on PCs was estimated from calculating the density of PCs in five sections at least 100 lm apart. Standard deviation is in parentheses.
bPercentage wild-type based on granule cells was estimated from counting of anti-NeuN-stained granule cells in three 65 3 65 lm regions from two sections at least 100 lm apart.
cSevere ataxia is defined as a balance beam score of two or less. Homozygous mutant ages are the average of three male and three female mice.
dThis small percentage of non-GFP PCs is likely an artifact from the thin sectioning; if a small fraction of a PC is in the section, it may not be scored GFP-positive. Examination of the same PC in the adjacent section shows that all PCs are in fact
GFP-positive.
eOnly lobule X PCs were used in estimating the wild-type contribution in mutant chimeric mice sacrificed at 70 d, prior to degeneration of this lobule.
fND indicates not determined, as this mouse was sacrificed prior to developing severe ataxia.
gNM indicates not meaningful, as lobule X PCs are only a useful measure of wild-type contribution when mice are sacrificed by 70 d.
CD1, CD-1 strain (Charles River Laboratories); C57, C57BL/6J strain (Jackson Laboratory).
DOI: 10.1371/journal.pgen.0010007.t001
Figure 2. Features of PC Loss in npc1 Mice
(A) Sections from the cerebellar vermis of a 70-d-old npc1
 / mouse were stained with anti-Calbindin (green) to visualize PCs and 7AAD (red) for nuclei.
Although there are scant PCs remaining in lobule II, the PCs in lobule X have not decreased.
(B) Quantification of progressive anterior-to-posterior PC loss. PC densities from 30-d npc1
þ/þ and 30-, 50-, and 70-d npc1
 /  mice were quantified from
five sections from two mice each. Error bars show standard deviation.
(C) Bergmann glia visualized in 70-d npc1
þ/þ and npc1
 /  mice using anti-S100b (green) have normal morphology. Note that the glial cell bodies near
the PC layer and the radial processes extending into the molecular layer are intact in the npc1
 /  mouse despite the loss of PCs.
(D) Oligodendrocyte cell bodies stained with anti-CC1 (green) have a similar distribution and morphology in the cerebellar white matter of 70-d npc1
 / 
and wild-type mice. TOTO-3 (red) was used as a nuclear counterstain. Bar ¼ 5 lm.
(E) Axonal spheroids in npc1
 /  mice. Spheroids (arrows), seen as Calbindin-positive (red) swellings surrounded by myelin (anti-myelin basic protein;
green), are numerous in the npc1
 /  cerebellum (50-d-old, lobule X shown) but are not seen in the wild-type control. Bar ¼ 5 lm.
(F) Sections from wild-type and npc1 mice were stained with filipin to visualize free cholesterol. PCs from npc1 mice show an accumulation of
intracellular cholesterol at 30 d regardless of their lobular location. Images are oriented such that the PCs (arrowheads) are in the center of the field,
with the molecular layer above and the inner granule cell layer below.
DOI: 10.1371/journal.pgen.0010007.g002
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(A) Genotyping of chimeric mice. Upper gel: PCR to amplify a fragment of the npc1 gene from npc1
 / $GFP, npc1
þ/ $GFP, and npc1
þ/ mice results in
npc1
  (1,067 bp) and npc1
þ (947 bp) bands. Lower gel: The three genotypes can be distinguished by ApaLI digestion of the PCR products. The npc1
 
allele gives rise to 937- and 130-bp bands. The wild-type allele varies depending on the source: the BALB/c allele is digested to 477-, 340-, and 130-bp
bands while the allele from the GFP mouse is digested to 817- and 130-bp bands. Note that the 477- and 340-bp bands are absent from the
homozygous mutant chimera.
(B) Quantification of npc1
 /  PC density in chimeric mice. For each mouse, the actual density observed (the average of the mean densities counted in
each lobule) is compared to the number expected if no PC loss occurs (calculated from the density at 30 d in npc1
 /  mice and the chimerism
percentage). Five sections separated by at least 100 lm were analyzed for each mouse. For the three mice sacrificed at 70 d, only lobules I–IX were
included in the analysis because of the lack of degeneration in lobule X in npc1
 /  mice at this age. A value for the number of npc1
 /  PCs expected if
loss does occur (calculated from the density at 70 d in npc1
 /  mice and the chimerism percentage) is also included for these three mice. No rescue of
npc1
 /  PCs was observed for any of the chimeric mice (p , 0.0001 for each mouse comparing observed versus expected if no loss occurs).
(C) Quantification of npc1
 /  PC density by lobule in C1.4 at 70 d. Observed and expected densities are shown for npc1
 /  PCs in each lobule. No clear
rescue of npc1
 / PCs was observed in any lobule (p . 0.05 for all lobules comparing observed versus expected if loss occurs, except II and III, where p-
value is between 0.01 and 0.05; p , 0.001 for all lobules comparing observed versus expected if no loss occurs, except lobule X, where p . 0.05).
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in mouse models of neurodegeneration (reviewed in [31]).
The cell death mechanism at work in NPC is unknown,
although a very recent report demonstrated TUNEL staining
and increased caspase-8 levels in npc1
 /  cerebellum, support-
ing a role for apoptosis in neurodegeneration in NPC [32].
We addressed this question by ultrastructural comparison of
wild-type and npc1 PCs using electron microscopy (EM). No
apoptotic bodies were identiﬁed by EM, nor did we identify
any TUNEL-positive PCs using immunoﬂuorescence labeling
of sections from 48-d-old npc1
 /  mice (data not shown).
In contrast, numerous structures with features consistent
with autophagic vacuoles (AVs) were identiﬁed in npc1 PCs by
EM. Previous EM studies of npc1 PCs [13,16] noted the
appearance of ‘‘lamellar inclusion bodies.’’ Such structures
are consistent with the activation of autophagy, although to
our knowledge there have been no reports of autophagy in
NPC. AVs can be classiﬁed as autophagosomes or autolyso-
somes based on morphological criteria [33,34]. Autophago-
somes are bound by two or more membranes and contain
seemingly unaltered cytoplasmic components. The autopha-
gic and endocytic pathways converge following fusion of
autophagosomes with late endosomes and subsequently with
lysosomes [35]. These fusion events result in autolysosomes,
organelles enclosed by a single limiting membrane with
degrading membranes and cellular components within.
Numerous AVs are found in PCs from 48-d-old npc1
homozygous mice (Figure 6A–6E). Such structures are rarely
seen in 48-d-old wild-type mice (Figure 6F–6H). Since NPC
cells accumulate lipids within organelles containing late
endocytic and lysosomal markers, the structures we identiﬁed
as AVs could be aberrant late endosomes or lysosomes, with
no autophagy involved. However, we can clearly identify
cytoplasmic contents (free ribosomes, endoplasmic reticulum
[ER] cisternae, and mitochondria) within these structures, a
diagnostic for AVs. Quantiﬁcation of AVs in wild-type and
npc1 PCs demonstrates that these structures occupy 15 times
more area in npc1 PCs (Figure 6I). Rarely, the cell body of an
npc1 PC ﬁlled up almost completely with autolysosomes
(Figure 6E). Degenerating PCs in npc1 mice clearly have
morphological features consistent with autophagic cell death.
Increased modiﬁcation of an autophagosomal marker
protein provides further evidence for the activation of
autophagy in npc1 cerebellum. During autophagy induced
by starvation or rapamycin, the light chain 3 (LC3) protein
undergoes lipid modiﬁcation by a ubiquitin-like conjugating
system [36,37]. This lipid-modiﬁed form of the protein (LC3-
II) associates with autophagosome membranes, and levels of
LC3-II correlate with the amount of autophagosome for-
mation [38]. In adult cerebellar cortex, LC3 protein is
reported to be present primarily in PCs, based on immuno-
ﬂuorescence studies [39]. The amount of LC3-II protein in
npc1
 /  cerebellum increases dramatically with age (Figure
7A). When 22-d-old mice are compared, LC3-II levels are
nearly equivalent. In wild-type mice, the level stays the same
or may slightly decrease in 50- and 67-d-old mice. In the
npc1
 /  mice, there was a 7- and 11-fold increase in LC3-II
compared to age-matched controls of these respective ages.
Thus, morphological and biochemical criteria show that
autophagy is activated in degenerating npc1
 /  cerebella.
To determine whether loss of npc1 is sufﬁcient to induce
autophagy in all cell types, we examined CT60 cells, a cell line
harboring a loss-of-function mutation in npc1 [40]. No
elevation of LC3-II was detected, though LC3-II accumulation
can clearly be induced in Chinese hamster ovary (CHO) cells
with rapamycin treatment (Figure 7B). The lack of autophagy
activation in an npc1 cell line and in cerebella from 22-d-old
npc1
 / mice suggests that autophagy is activated only in npc1
 /
  cells actively undergoing degeneration.
Discussion
Neurodegeneration is among the most devastating and
feared types of human disease. No treatments exist that stop
neurodegeneration and very few even provide transient
symptomatic relief [41]. Alzheimer disease, the most common
cause of dementia, affects roughly 12 million people world-
wide [42]. Even for Alzheimer disease the pathophysiology is
unclear. It is still controversial whether extracellular or
intracellular beta-amyloid deposits are responsible for the
bulk of neurotoxicity [43,44], and the importance of
inﬂammation to progression of the disease is unknown
[45,46]. For most neurodegenerative diseases, how much
neuronal loss can be attributed to cell-autonomous versus
non-cell-autonomous factors is unknown. We examined this
crucial question in the neurodegenerative disorder NPC.
People born with NPC disease undergo a progressive
decline in neurological function that can include ataxia,
tremor, dystonia, dementia, and seizures. As the prominent
ataxia would suggest, cerebellar involvement, including PC
degeneration, has been well documented [47–49]. The mouse
model of NPC faithfully recapitulates many of the human
symptoms, and PC loss serves as an easily quantiﬁable
measure of neurodegeneration. The involvement of circulat-
ing molecules such as steroids and sterols, and the ubiquitous
expression of both NPC genes, make determining when and
where the NPC genes are required a key ﬁrst step in
understanding neurodegeneration. A previous study high-
lighted the importance of events within the central nervous
system, as expression of Npc1 driven by the prion promoter
could prevent neurodegeneration even without complete
rescue of the liver phenotype [30]. In this study we have found
that the most prominent neurodegenerative event, the death
(D and E) Images of lobules II and X taken from C1.4 at 70 d. GFP is green and Calbindin staining is red. In lobule II, the number of PCs is clearly reduced
and of the five remaining PCs, four are wild-type (GFP-positive). In lobule X (where no degeneration occurs during the normal npc1
 /  life span), PC
density is normal and the majority of PCs (23 of 32; 72%) are mutant, as expected based on npc1
 /  contribution to this mouse (67%).
(F) Quantification of wild-type PC density in chimeric mice. Observed and expected densities are shown for wild-type PCs. For mice with more than 15%
wild-type contribution, the density of wild-type PCs is similar to the number expected if these cells have not degenerated (p . 0.05 for each mouse
comparing observed versus expected if no loss occurs, except C5.2, where p ¼ 0.02, and C5.6, where p ¼ 0.0005).
(G) Quantification of wild-type PC density by lobules in C1.4 at 70 d. No loss of wild-type PCs was observed in any of the lobules (p . 0.05 for all lobules
comparing observed versus expected if no loss occurs; p , 0.001 for all lobules comparing observed versus expected if loss occurs, except for lobule X,
where p . 0.05).
DOI: 10.1371/journal.pgen.0010007.g003
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Cell-Autonomous Neurodegeneration in NPCof the PCs, is due to lost Npc1 function within those cells and
to a distinctive programmed cellular response, autophagy.
Cell-Autonomous PC Death in NPC Disease
We have demonstrated that the loss of PCs in the mouse
model of NPC, which has a mutant npc1 gene, is primarily a
cell-autonomous defect. This ﬁnding places constraints on
possible mechanisms of PC degeneration in NPC disease, and
allows future investigations to focus on the cell type that
matters. As is described in the introduction, several lines of
evidence hinted that neurodegeneration in NPC disease
could be a non-cell-autonomous process. However, the
inability of a wild-type milieu, including surrounding wild-
type glia, to prevent npc1
 /  PC loss indicates that the
degeneration of PCs is not due to the loss of a secreted
factor such as glia-derived sterols, neurotrophins, or Npc2
protein. Consistent with this, two very recent studies failed to
detect a difference in levels of secretion of cholesterol from
wild-type versus npc1
 /  glia [50,51].
Figure 4. Other Histological Characteristics in the npc1 Mutant and Chimeric Mice
(A–C) Microglia characteristics. Sections from 50-d-old npc1 mutants were stained with anti-Calbindin (green) to visualize PCs and anti-F4/80 (red) to
mark microglia. (A) Very few microglia are present in lobule X, where no PC degeneration has yet occurred. (B) Lobule VIII demonstrates an infiltrationo f
microglia in the granule cell layer and white matter tract. (C) In lobule II, nearly all PCs are gone and numerous microglia are present throughout the
cerebellum. The dashed line indicates the edge of the granule cell layer.
(D) Microglia infiltration is not sufficient to induce PC degeneration. C1.4 demonstrates numerous microglia marked by anti-F4/80 (red) in all layers of
the cerebellum, including immediately adjacent to wild-type (GFP-positive) PCs (arrows). Despite this close approximation, no loss of wild-type PCs was
detected by cell counting. The GFP transgene is apparently poorly expressed in microglia, as all microglia appear GFP-negative regardless of their
genotype.
(E) Mutant PCs are lost even when surrounded by wild-type Bergmann glia. A stretch of the PC layer in C4.8 is shown where no npc1
 /  (GFP-positive)
PCs remain despite the presence of numerous wild-type (GFP-negative) glia (arrowheads) marked by anti-S100b (red). The space occupied by two wild-
type PCs is indicated (arrows) with two npc1
 /  (GFP-positive) glia directly underneath.
(F) Wild-type PCs do not degenerate even when surrounded by mutant Bergmann glia. Three wild-type PCs (GFP-positive; arrows) in C1.4 have not
degenerated despite only mutant glia (arrowheads) being in the immediate vicinity.
(G) Oligodendrocytes in chimeric mice are a mixture of wild-type and mutant cells. Oligodendrocyte cell bodies are stained with anti-CC1 (red). Wild-
type (GFP-positive; arrows) and npc1
 /  (GFP-negative; arrowheads) oligodendrocytes are interspersed in C1.4.
Bar ¼ 50 lm for (A), (D), and (G); 10 lm for (E) and (F).
DOI: 10.1371/journal.pgen.0010007.g004
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could be affected by their axonal targets in the cerebellar
deep nuclei. Expression of GFP is very low in neurons of the
cerebellar deep nuclei in the GFP mice (data not shown), so
we were unable to assess the genotype of these cells in the
chimeras. During the migration of PCs, their axons do not
remain attached to their future post-synaptic targets [52]. If
PC death in npc1 mice was caused by loss of a target-derived
factor, then the absence of a genotypic match between target
neurons and PCs would mean that wild-type and npc1 PCs
should be equally affected. This is not what we observe. In
addition, completely depriving PCs of their axonal targets by
axotomy does not cause PC degeneration even up to a year
following axotomy [53,54]. Thus, derangement of cerebellar
deep nuclei is unlikely to be causing PC degeneration in NPC.
Secreted or released toxic molecules are also not respon-
sible for PC death. Microglia produce pro-inﬂammatory and
cytotoxic compounds including cytokines, proteases, and free
radicals [55–57] and are present in higher-than-normal
numbers in the NPC mutant cerebellum [28]. A robust
inﬂammatory response may play a role in the progressive
neurodegeneration seen in NPC but is not the primary factor
in causing neuronal loss: in the chimeric mice most wild-type
PCs do not degenerate even while in the midst of numerous
microglia. Our experiments do not exclude a more cell-
speciﬁc role for microglia in PC death. Microglia could help
trigger cell death by speciﬁc molecular interactions with
susceptible PCs, as is proposed to occur during PC death
normally seen at postnatal day 3 [58]. A microglia-based
mechanism would require a cell-autonomous component—
PCs expressing the proper membrane receptors—and a non-
Figure 5. Organismal Phenotypes in Chimeric Mice
(A) Chimeric mice with more than 50% wild-type contribution do not exhibit wasting. Weekly weights for each of the mice were recorded from 4 wk
until the mice were sacrificed. For wild-type and npc1
 / homozygous mice, the curve shown is the mean weight from three to four mice. A progressive
decrease in weight of npc1 mice begins to show around 7 wk. The chimeric mice display a delay in, or even absence of, wasting depending on the
amount of wild-type contribution.
(B) Prevention of ataxia in chimeric mice. Mice were assessed for ataxia weekly during two 3-min trials on a balance beam (see Materials and Methods).
(C) Gait of chimeric mice. Front and back paws of mice were dipped in red or green paint, and mice walked across a box lined with paper. The npc1
 / 
mouse displays shorter stride length and a smearing of the footprints as the paws are not as well lifted between steps. Chimeric mice with high
amounts of wild-type contribution (C4.8; C4.4 not shown) exhibited a gait indistinguishable from wild-type.
(D) Quantification of stride length. For wild-type and mutant controls, three mice were assessed. For chimeric mice, gait was measured prior to sacrifice
at the ages noted. Error bars indicate the standard deviation. Comparison with the GFP mice demonstrates that npc1
þ/þ, C1.4, C4.4, and C4.8 do not
have significantly different stride lengths (p . 0.05) while npc1
 / , C5.2, C5.6, C2.1, and C5.8 have significantly shorter stride lengths (p , 0.001)
DOI: 10.1371/journal.pgen.0010007.g005
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EM of npc1
 /  and wild-type PCs from anterior vermis of 48-d-old mice.
(A) Low-power field of a typical npc1 PC.
(B) Magnification of the red box in (A) showing accumulated multivesicular and multilamellar organelles.
(C) Magnification of the blue box in (A) showing a large AV (arrowheads) containing ribosomes and membranes.
(D) Another AV (arrowhead) with ER cisternae within the lumen.
(E) An npc1 PC probably in the late stages of degeneration, with many AVs, some with apparently degrading mitochondria (arrowheads).
(F) Low-power field of two wild-type PCs.
(G and H) Magnification of the red (G) and blue (H) boxes in (F) showing no AVs and very few multivesicular organelles (arrow).
(I) Quantification of area occupied by AVs and other multivesicular/multilamellar organelles expressed as a percentage of total cytoplasmic area for
seven wild-type and seven npc1
 /  PCs; p ¼ 0.0009 for comparing AV areas and p ¼ 0.0003 for comparing other multivesicular/multilamellar areas,
indicating both types of organelles occupy significantly more area in npc1
 /  PCs.
Bar ¼ 5 lm for (A) and (F); for all others, bar ¼ 1 lm.
DOI: 10.1371/journal.pgen.0010007.g006
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directed engulfment of only those cells.
Internal Factors in Neurodegeneration
PCs may degenerate either (1) because the buildup of
sterols and other lipids, or other unknown substances,
poisons the PCs or (2) because trafﬁcking defects resulting
from Npc1 loss affect cell survival. Although excess choles-
terol can have toxic effects [21], intracellular cholesterol
levels within PCs do not correlate with the loss of these cells:
lobule X PCs accumulate cholesterol and do not degenerate
during the 70 d that normally constitute the npc1 mouse life
span. More subtle differences among lobules, in sterol mass or
subcellular localization of cholesterol, are unlikely to be
detected with ﬁlipin staining. In any case, blocking lipid
accumulation is insufﬁcient to slow neuronal loss, again
arguing against the idea that cell death occurs because of
accumulated lipid. Crossing the npc1 mouse to a GalNAcT-
knockout mouse unable to synthesize complex gangliosides
decreases levels of sphingolipids and cholesterol without any
effect on neurodegeneration [59]. Crossing the npc1 mouse to
a low density lipoprotein receptor knockout also does not
slow neurodegeneration [60]. Although both of these experi-
ments have their weaknesses—possible buildup of less
complex sphingolipids in the GalNAcT experiment and
possible redundancy in lipoprotein receptors in the low
density lipoprotein receptor knockout—the ﬁndings at least
suggest that intracellular toxicity due to lipid accumulation is
not the primary mechanism of PC death.
Defects in lipid trafﬁcking are likely to have particularly
detrimental effects on synthetic processes that rely on lipids
as substrates. A recent study demonstrates that neurosteroid
synthesis is reduced in npc1 mice and administration of
allopregnanolone increases life span and neuronal survival
[61]. PC loss involving interference with production of
neurosteroids acting in a paracrine or endocrine manner is
untenable in light of our ﬁndings. An autocrine mechanism
of action, with PCs making substances that act in the
producing cell, is still plausible and needs to be explored
further. PCs synthesize several different neurosteroids and
express progesterone receptors [62]. PCs are unique in having
an extensive smooth ER, the ‘‘hypolemmal cisternae,’’ that is
‘‘so well developed in PCs that it may be considered a speciﬁc
characteristic...since it extends under the plasmalemma of
the entire cell body, the dendritic tree, and the axon’’ [63].
Palay and Chan-Palay [63] also note that mitochondria are
often found against the inner surface of the hypolemmal
cisternae. Impaired cholesterol trafﬁcking to mitochondria
and the smooth ER may lead to a deﬁciency at these sites,
lowering the production of neurosteroids.
Autophagy in NPC PC Death
Loss of npc1 function within PCs leads to increased
autophagy and cell death. Apoptosis may also be involved
in the death of neurons from NPC disease; both processes are
likely at work in the degenerating NPC brain. In contrast to
apoptosis, which has been demonstrated in many instances of
neurodegeneration (reviewed in [31]), activated autophagy
has been demonstrated in only a few cases, but notably
including death of PCs in Lurcher mice [64]. The role of
autophagy in neurodegenerative disease extends to Hunting-
ton disease and Parkinson disease [65–67]. These neuro-
degenerative diseases differ from NPC in that they are
disorders of protein aggregation. Formation of insoluble
aggregates of Huntingtin or alpha-synuclein is an early event
in disease progression [68–71]. Autophagy may be activated
by cells in order to dispose of the aggregates. Deliberately
enhancing degradation of protein aggregates by triggering
autophagy in animal models of Huntington disease can
Figure 7. Levels of the Autophagosomal Marker LC3-II Are Increased in
Degenerating npc1 Cerebellum
(A) Immunoblots of 70 lg of protein resolved by 15% SDS-PAGE show
increased levels of LC3-II in 50- and 67-d-old npc1 cerebellar extracts.
Two mice of each age and genotype were analyzed, and relative band
intensities were quantified. p-Values derived from comparing wild-type
and npc1
 / cerebella at each age are 0.3, 0.01, and 0.001 for 22-, 50-, and
67-d-old mice, respectively.
(B) Immunoblots of CHO cell extracts resolved by 15% SDS-PAGE do not
show increased levels of LC3-II in CT60 cells compared to wild-type CHO-
KI cells or CT60 cells stably transfected with NPC1-YFP. No difference is
noted with 10 lM U18666A, a drug that mimics npc1 loss of function.
Rapamycin treatment (1 lM) of CHO-KI cells demonstrates robust
activation of autophagy with increased LC3-II levels.
DOI: 10.1371/journal.pgen.0010007.g007
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aggregation has been reported in NPC, but an analogous
mechanism could be at work: during the ﬁrst several weeks of
life, cells may activate autophagy to degrade the abnormal
lipid-laden lysosomes and allow the survival of PCs. If this is
true, then cells with lipid-laden lysosomes should have high
autophagic activity. This prediction is clearly contradicted by
our data: activation of autophagy is seen only in older,
degenerating PCs, and npc1 cells not undergoing cell death do
not exhibit increased levels of the autophagic marker LC3-II.
Why then is autophagy induced in degenerating PCs?
Autophagy is a normal, cellular process that is regulated by
nutritional status and by hormones. Loss of npc1 leads to
trapping of lipids within aberrant membrane compartments,
and this may induce a ‘‘lipid-starvation response’’ analogous
to the well-characterized autophagic response to amino acid
deprivation. In fact, there is already evidence that such a
response occurs in npc1 homozygotes: despite the seeming
overabundance of cholesterol in npc1
 /  cells, the SREBP
signaling pathway is activated. This results in increased
cholesterol synthesis and low density lipoprotein receptor
activity [72]. Thus, NPC cells act as though they are
‘‘cholesterol starved.’’ NPC cells therefore may have three
ways to adjust to a shortage of sterols and other lipids:
increased lipid synthesis, increased lipid uptake, and autoph-
agy. Microarray analysis of SREBP targets in liver [73] did not
reveal increased transcription of autophagy genes, but the
targets may differ between tissues, or regulation may occur at
the post-transcriptional level. In NPC cells, the autophagic
response would be futile since transport systems are damaged.
Instead of rescuing the cell, autophagy would hasten cell death
by further sequestering and reducing available lipids.
Destructive autophagy in NPC mutant PCs may also, or
instead, be stimulated hormonally. In mammals, autophagy is
inhibited by insulin [74], and in insects, steroids regulate
autophagy of neurons by a cell-autonomous mechanism
[75,76]. In Manduca (tobacco hawkmoth) motor neurons and
in salivary glands and fat body of Drosophila, the steroid
ecdysone triggers autophagy at speciﬁc developmental time
points. We would infer a different regulatory relationship in
mammalian NPC. Neurosteroids might inhibit autophagy in
PCs and when their synthesis is severely decreased, as in NPC
[61], autophagic cell death might ensue. Neurotrophins may
also be involved in regulating PC autophagy. Cultured PCs
undergo autophagic cell death following neurotrophin with-
drawal [77]. These ﬁndings are relevant to NPC because
neurons from NPC mice have decreased responsiveness to
neurotrophins [78].
LevelsofCerebellumInvolvementinChimericnpc1
 / Mice
The chimeric mice also provide information about the
progression of the disease. Homozygous npc1 mice at 70 d are
unable to maintain posture on the balance beam for even a
few seconds and weigh only half as much as controls.
Remarkably, some chimeras had only minimal ataxia and no
wasting despite the loss of approximately 40% of PCs. The
minimal ataxia phenotype, manifested as occasional falls off
the balance beam while turning, stopped progressing by
approximately 140 d. By this age, nearly all mutant PCs,
including those in lobule X, had died. Presumably ataxia
worsens until all mutant PCs die, at which point the
phenotype stabilizes.
With so many PCs lost, other regions of the brain, other
cerebellar cells, or the remaining PCs may compensate.
Morphological changes that have been observed in the
remaining npc1 neurons, such as occurrence of ectopic
dendritic spines and meganeurites [26,79] and increased
width of the dendritic tree [80], may be the physical
manifestations of the remaining PCs taking on functions of
their deceased counterparts. Compensation may also occur in
other regions of the brain. In the pcd and Lurcher mouse
models, compensatory mechanisms in the efferent targets of
the PCs, the cerebellar deep nuclei, have been postulated to
be responsible for the mild ataxia that occurs despite severe
PC loss [81]. Lurcher chimeric mice, in which PCs undergo
cell-autonomous loss, have no behavioral abnormalities even
when they have few wild-type cells [82]. Recent studies using
this model of PC degeneration have deﬁned a minimum
number of PCs required for normal motor control between
1,000–7,000, or roughly 1%–5% of the normal number of PCs
[83,84]. Thus, the loss of PCs may be signiﬁcantly ameliorated
by still-to-be-identiﬁed mechanisms, and slowing loss of PCs
by any mechanism may allow increased compensation. Some
of the phenotypes of the npc1
 /  mouse are likely to be due to
loss or derangement of other cells, such as certain popula-
tions of neurons in the thalamus [85] or dorsal root ganglion
[86]. There appears to be a critical threshold of wild-type
contribution between 30% and 60% required for near-
complete rescue of both ataxia and weight loss. The delayed
progression seen with low levels of wild-type cells (approx-
imately 15%) is quite encouraging with respect to the
potential for therapies that preserve even some of the cells.
Several questions regarding the loss of PCs in NPC have
been answered in this study. Of four possible mechanisms of
PC loss (see Figure 1), the chimeric mice demonstrate that the
two strictly non-cell-autonomous models are invalid. Of the
two cell-autonomous models, internal toxicity versus sub-
cellular deﬁciency, we favor the latter based on the observed
defects in organelle trafﬁcking in npc1 cultured cells [87,88],
the lack of correlation between cholesterol levels and PC loss,
the decreased levels of steroidogenesis in npc1 mice [61], and
the previous transgenic studies designed to decrease choles-
terol or sphingolipid accumulation [59,60]. We envision that
in response to the proposed intracellular deﬁciency, cells
compensate by increasing endogenous synthesis of cholester-
ol, by endocytosis, and/or by autophagy. In cells with a high
lipid demand and insufﬁcient supply, autophagy increases
and cell death ensues. It may be that a similar series of
events—defective trafﬁcking leading to subcellular deﬁciency
and autophagic cell death—occurs in many other lysosomal
storage diseases. To our knowledge, Danon disease, caused by
deﬁciency in the lysosomal membrane protein LAMP-2, is the
only other lysosomal storage disease that has a demonstrated
increase in AVs [89]. The pattern of degeneration erupting in
each disease would be determined by the cell-speciﬁc
response to being deprived of a particular molecule or class
of molecules. PCs appear to be highly sensitive to insufﬁcient
levels of sterols or sterol metabolites (and perhaps also to
sphingolipid deﬁciency, since PC loss is prominent in
Niemann-Pick type A as well [90,91]).
Our results are particularly interesting in light of the two
other human neurodegenerative diseases that have been
analyzed with chimeric mouse models. In amyotrophic lateral
sclerosis, surrounding wild-type non-neuronal cells can
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and the genotype of the motor neurons themselves appears to
have no bearing on their probability of survival [23]. In the
mnd mouse, a model for neuronal ceroid lipofuscinosis,
proteolipid storage is cell-autonomous, but retinal degener-
ation equivalent to the mnd controls was seen in all chimeric
mice [24]. The fact that three neurodegenerative diseases
examined with this experimental approach exhibit three
different modes of degeneration (non-cell-autonomous res-
cue for amyotrophic lateral sclerosis, cell-autonomous stor-
age but non-cell-autonomous degeneration for neuronal
ceroid lipofuscinosis, and cell-autonomous autophagic death
for NPC) demonstrates the remarkable diversity in neuronal
degeneration mechanisms and highlights how much still
needs to be learned about the biology of neurodegeneration.
Materials and Methods
Materials. BALB/c npc1
nih, FVB.Cg-Tg(GFPU)5Nagy/J, and C57BL/6J
mice were obtained from Jackson Laboratory (Bar Harbor, Maine,
United States). CD-1 mice were from Charles River Laboratories
(Wilmington, Massachusetts, United States). Mouse anti-Calbindin D-
28K (1:250 dilution used), mouse anti-S100b (1:250) ascites, rapamy-
cin, and ﬁlipin were obtained from Sigma (St. Louis, Missouri, United
States). Rabbit anti-GABAa6 (1:250), rabbit anti-NeuN (1:100), and rat
anti-myelin basic protein (1:500) were obtained from Chemicon
International (Temecula, California, United States). Rat anti-F4/80
(1:100) was obtained from Serotec (Raleigh, North Carolina, United
States). Mouse anti-CC1 (1:100) was from EMD Biosciences (San
Diego, California, United States). Rabbit anti-MAP LC3 (1:1,000) was
the kind gift of Marlene Rabinovitch and Lihua Ying (Stanford
University, Palo Alto, California, United States). Nuclear dyes 7AAD
and TOTO-3 were obtained from Molecular Probes (Eugene, Oregon,
United States).
Generation of npc1 chimeric mice. Aggregation chimeras were
made according to established procedures [92]. Mice made up of npc1
cells and GFP-expressing wild-type cells were constructed using
BALB/c npc1
nih and FVB.Cg-Tg(GFPU)5Nagy/J embryos. In order to
make reciprocal chimeras, npc1 heterozygous mice were mated to
FVB.Cg-Tg(GFPU)5Nagy/J mice. Offspring heterozygous for npc1 and
GFP were backcrossed to FVB.Cg-Tg(GFPU)5Nagy/J mice to obtain
mice heterozygous for npc1 and homozygous for GFP. Sibling matings
were used to generate GFP-expressing npc1
 /  embryos. Wild-type
embryos were obtained from CD-1 and C57BL/6J strains. Week-old
pups were examined with a blue LED and blue-ﬁltering glasses to
determine the ratio of mutant to wild-type cells based on skin
ﬂuorescence. The percentage of mutant cells in chimeras made with
the C57BL/6J strain was also evaluated by measuring relative areas of
coat color; the results were consistent with the percentage of GFP
ﬂuorescent cells.
Tail preparation DNA was used to genotype mice using PCR
primers for npc1 [6]. To distinguish between the wild-type npc1 alleles
in the BALB/c, FVB.Cg-Tg(GFPU)5Nagy/J, CD-1, and C57BL/6J strains,
we took advantage of a polymorphism that could be detected with an
ApaLI restriction digest. Digestion of the BALB/c, CD-1, or C57BL/6J
wild-type PCR product results in 477-, 340-, and 130-bp fragments;
the FVB.Cg-Tg(GFPU)5Nagy/J wild-type PCR product digest results in
817- and 130-bp fragments; the mutant npc1 PCR product digest
results in 937- and 130-bp fragments. Therefore, for npc1
 / 
$FVB.Cg-Tg(GFPU)5Nagy/J mice, we expect 937-, 817-, and 130-bp
bands. For npc1 / ;GFPþ/þ$CD-1 or C57BL/6J mice, we expect 937-,
477-, 340-, and 130-bp bands.
Mouse assays. Mice were weighed weekly on a gram scale. For
balance beam measurements, mice were placed perpendicularly on a
stainless steel bar (2 cm in diameter, 120 cm in length) wrapped in
laboratory tape as described [29]. Alternating 10-cm segments were
marked by varying tape color. The level of ataxia was assessed based
on time (180 s maximum), number of sections crossed, and
qualitatively on a ﬁve-point ataxia scale: ﬁve, no ataxia; four, inability
to turn around on the bar; three, difﬁculty walking to the end of the
bar without falling off; two, the mouse can only cling to the bar and is
unable to correct itself from its initial perpendicular orientation; and
one, postural instability as the mouse quickly falls off the bar even
when placed along the long axis.
For gait assays, front paws were dipped in red paint and back paws
in green paint, and mice were placed on Whatman paper at one end
of a 14 3 44 cm box. The distance between the back edge of each
same-side paw print was used to determine stride length.
Cerebellar sectioning and staining. Mice were anesthetized with
avertin and perfused with 4% PFA. Brains were post-ﬁxed for 24 h in
4% PFA, transferred to 25% sucrose overnight, embedded and frozen
in OCT, and cut into 12-lm sections with a cryostat.
For immunostaining, sections were rehydrated in PBS and blocked/
permeabilized with 10% normal goat serum and 0.2% Triton X-100
in PBS. Incubation with primary antibody was carried out overnight
at 4 8C. Following three washes with PBS, sections were incubated for
2–4 h with the appropriate ﬂuorescently conjugated secondary
antibody. Sections were washed again and mounted with Fluo-
rmount-G (Southern Biotechnology Associates, Birmingham, Alaba-
ma, United States). Filipin staining was carried out with 50 lg/ml
ﬁlipin following treatment with 0.02% saponin as described
previously [79].
PC counts. All PCs in ﬁve sections at least 100 lm apart were
counted for each mouse. The length of the PC layer was measured
using MetaMorph software (Universal Imaging, Downington, Penn-
sylvania, United States), and the density was determined by dividing
the number of PCs by this length. Expected densities if no
degeneration has occurred were calculated by multiplying the
percentage of chimerism by the density of PCs observed in npc1
mice at 30 d. PC densities in the three chimeric mice sacriﬁced at 70 d
were also compared to expected densities with degeneration
(calculated from the percentage of chimerism and the density of
PCs observed in npc1 mice at 70 d). p-Values were calculated with the
unpaired t-test or one-way ANOVA with Tukey’s multiple compar-
ison test using GraphPad Prism (GraphPad Software, San Diego,
California, United States).
LC3 immunoblotting. Cell extracts were obtained by solubilization
with 2% IGEPAL-CA630, 0.2% SDS, and mini complete protease
inhibitor tablet (Roche Applied Science, Indianapolis, Indiana,
United States) in PBS, followed by centrifugation at 10,000 RPM for
10 min. Extracts were kept on ice and resolved with 15% SDS-PAGE.
Following transfer to PVDF membrane (Bio-Rad, Hercules, Califor-
nia, United States), blocking was accomplished with 5% milk in PBS
plus 0.1% Triton X-100. Primary incubation with anti-LC3 (rabbit,
1:1,000 in 1% milk PBST) was carried out overnight at 4 8C. Following
three washes, the membrane was incubated with anti-rabbit-HRP
(1:10,000), washed three times, and developed with WestPico reagent
(Pierce Biotechnology, Rockford, Illinois, United States).
Electron microscopy. Mice were anesthetized using avertin and
were perfused with PBS followed by a solution of 2.5% glutaralde-
hyde and 4% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4)
for 15 min using gravity ﬂow. For microwave processing, a Pelco
laboratory microwave equipped with variable wattage, Cold Spot
water recirculator, and vacuum chamber was used (Ted Pella,
Mountain Lakes, California, United States). Brains were removed,
immersed in the same ﬁxative, and microwaved at 100 W for 1 min
on, 1 min off, 1 min on, with the Cold Spot set at 15 8C. A vacuum
chamber was applied and the brains microwaved at 450 W for 20 s on,
20 s off, 20 s on, three times. After an additional 15 min at room
temperature, the cerebellum was dissected away and sliced into
anterior and posterior samples. Post-ﬁxation was carried out using
2% osmium tetroxide containing 0.8% potassium ferricyanide and
5% sucrose in 0.1 M cacodylate buffer (pH 7.4) using the same
microwave parameters as for primary ﬁxation and followed by an
additional 45 min at room temperature. After rinsing in distilled
water, the tissue was dehydrated in an ascending alcohol (50%–95%)
series at 350 W for 45 s, then switched to 100% ethanol under vacuum
for 1 min on, 1 min off, 1 min on, three times. The tissue was
microwaved in 100% acetone for 1 min on, 1 min off, 1 min on, at
power level 3 using the vacuum chamber. The tissue was then
inﬁltrated in Epon-Araldite-acetone mixture in the microwave for 4
min on, 4 min off, 4 min on, at 350 W for each resin mixture (1:2, 1:1,
2:1) under vacuum. For the ﬁnal inﬁltration, the samples were placed
in 100% resin and microwaved at 350 W under vacuum for 10 min
on, 10 min off, 10 min on. The samples were embedded in fresh Epon-
Araldite and hardened at 65 8C for 1–2 d. Semi-thin sections (1–2 lm)
were cut using a Histoknife (Diatome, Fort Washington, Pennsylvania,
United States) and stained with toludine blue. Thin sections (70 nm)
were cut and mounted on formvar-coated multi-slot grids. Sections
were post-stained with 5% aqueous uranyl acetate and lead citrate
and examined at 80 kV in a JEOL (Tokyo, Japan) 1230 electron
microscope. Digital images were captured with a Gatan (Pleasanton,
California, United States) 967 slow-scan, cooled CCD camera. Images
were analyzed with ImageJ Software (National Institutes of Health,
Bethesda, Maryland, United States).
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